Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells

Haematologica. 2022 Feb 1;107(2):427-436. doi: 10.3324/haematol.2020.267583.

Abstract

Graft-versus-host disease (GvHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. We recently showed in murine studies and in vitro human models that adoptively transferred invariant natural killer T (iNKT) cells protect from GvHD and promote graft-versus-leukemia effects. The cellular mechanisms underlying GvHD prevention by iNKT cells in humans, however, remain unknown. In order to study relevant cellular interactions, dendritic cells (DC) were either generated from monocytes or isolated directly from blood of healthy donors or GvHD patients and co-cultured in a mixed lymphocyte reaction (MLR) with T cells obtained from healthy donors or transplantation bags. Addition of culture-expanded iNKT cells to the MLR-induced DC apoptosis in a cell contact-dependent manner, thereby preventing T-cell activation and proliferation. Annexin V/propidium iodide staining and image stream assays showed that CD4+CD8-, CD4-CD8+ and double negative iNKT cells are similarly able to induce DC apoptosis. Further MLR assays revealed that conventional DC (cDC) but not plasmacytoid DC (pDC) could induce alloreactive T-cell activation and proliferation. Interestingly, cDC were also more susceptible to apoptosis induced by iNKT cells, which correlates with their higher CD1d expression, leading to a bias in favor of pDC. Remarkably, these results could also be observed in GvHD patients. We propose a new mechanism how ex vivo expanded human iNKT cells prevent alloreactivity of T cells. iNKT cells modulate T-cell responses by selective apoptosis of DC subsets, resulting in suppression of T-cell activation and proliferation while enabling beneficial immune responses through pDC.

MeSH terms

  • Animals
  • Apoptosis
  • Dendritic Cells
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / prevention & control
  • Humans
  • Lymphocyte Activation
  • Mice
  • Natural Killer T-Cells*

Grants and funding

Funding: This study was supported by a Max Eder Research fellowship of the German Cancer Aid (Deutsche Krebshilfe, 70112548), a Junior Research Group Grant of the Interdisciplinary Center for Clinical Research (IZKF, 2316-0-0) and the Clinician Scientist Program of the Faculty of Medicine Tuebingen. HS received a grant from the Ludwig Hiermaier Foundation. CS was funded by a Junior Research Group Grant of the Interdisciplinary Center for Clinical Research (IZKF, 2383-0-0), the Clinician Scientist Program of the Faculty of Medicine Tuebingen and the Wuerttemberg Cancer Award (Wuerttembergischer Krebspreis). The National Institutes of Health Tetramer Core Facility kindly provided CD1d tetramer reagents.